Skip to main content

Table 3 Association of MCT expression with the clinical-pathological parameters

From: Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization

Clinical-pathological data MCT1 (PM) MCT1 (nucleus) MCT4 (PM)
n Positive (%) p Positive (%) p Positive (%) p
Age    0.153   0.076   0.403
 >51 48 32 (66.7)   12 (25.0)   29 (60.4)  
 ≤51 37 19 (51.4)   16 (43.2)   19 (51.4)  
Gender    0.716   0.174   0.463
 Female 33 19 (57.6)   8 (24.2)   17 (51.5)  
 Male 52 32 (61.5)   20 (38.5)   31 (59.6)  
Race    0.686   0.896   0.832
 Caucasian 63 37 (58.7)   21 (33.3)   36 (57.1)  
 Not Caucasian 22 14 (63.6)   7 (31.8)   12 (54.5)  
Local    0.586   0.439   0.154
 Lower extremities 63 37 (58.7)   22 (34.9)   33 (52.4)  
 Upper extremities 23 15 (65.2)   6 (26.1)   16 (69.6)  
Cell lineage    0.066   <0.001   <0.001
 Fibroblastic/myofibroblastic 28 16 (57.1)   9 (32.1)   16 (57.1)  
 Smooth muscle 17 12 (70.6)   3 (17.6)   13 (76.5)  
 Lipogenic 17 6 (35.3)   13 (76.5)   2 (11.8)  
 Peripheral nerve 7 4 (57.1)   2 (28.6)   4 (57.1)  
 Miscellaneous 17 14 (82.4)   1 (5.9)   14 (82.4)  
Cellular pleomorphism    0.034   0.010   0.009
 Absence of pleomorphic cells 54 28 (51.9)   23 (42.6)   25 (46.3)  
 Presence of pleomorphic cells 32 24 (75.0)   5 (15.6)   24 (75.0)  
Grade    <0.001   <0.001   0.011
 Low grade (I) 19 4 (21.1)   14 (73.7)   6 (31.6)  
 High grade (II e III) 67 48 (71.6)   14 (20.9)   43 (64.2)  
Disease progression    0.018   0.865   0.060
 No 25 10 (40.0)   8 (32.0)   10 (40.0)  
 Yes 56 39 (67.2)   20 (33.9)   35 (62.5)  
Disease recurrence    0.847   0.640   0.204
 Absent 48 29 (60.4)   15 (31.2)   24 (50.0)  
 Present 36 21 (58.3)   13 (36.1)   23 (63.9)  
Metastasis    0.156   0.122   0.249
 Absent 44 23 (52.3)   18 (40.9)   22 (50.0)  
 Present 40 27 (67.5)   10 (25.0)   25 (62.5)  
  1. PM- Plasma membrane.
  2. Significant values are shown in bold.